Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review

Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review

Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity. There is no disease-modifying treatment currently available. Therefore, standardized, validated outcome measures to facilitate clinical trials are urgently needed. We performed a scoping review of outcome meas...

Full description

Bibliographic Details
Main Authors: Sue-Faye Siow, Dennis Yeow, Laura I. Rudaks, Fangzhi Jia, Gautam Wali, Carolyn M. Sue, Kishore R. Kumar
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Genes
Subjects:
hereditary spastic paraplegia
outcome measures
biomarkers
clinical trials
scoping review
Online Access:https://www.mdpi.com/2073-4425/14/9/1756

Internet

https://www.mdpi.com/2073-4425/14/9/1756

Similar Items